ストックスクリーナーアプリを入手
5.14
3.21%
0.16
アフターアワーズ：
5.14
前日終値:
$4.98
開ける：
$4.93
24時間の取引高:
407.53K
Relative Volume:
2.53
時価総額：
$285.75M
収益：
$34.16M
当期純損益:
$-98.43M
株価収益率:
-1.8759
EPS:
-2.74
ネットキャッシュフロー:
$-119.33M
1週間 パフォーマンス:
-3.02%
1か月 パフォーマンス:
-34.61%
6か月 パフォーマンス:
-1.91%
1年 パフォーマンス:
-14.05%
1日の値動き範囲:
$4.88
$5.28
1週間の範囲:
$4.57
$5.6967
52週間の値動き範囲:
$2.70
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
名前
Foghorn Therapeutics Inc
セクター
電話
617-586-3100
住所
500 TECHNOLOGY SQUARE, CAMBRIDGE
FHTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
5.14 | 285.75M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-03 | 開始されました | Jefferies | Buy |
| 2024-08-19 | 開始されました | Evercore ISI | Outperform |
| 2023-03-28 | 開始されました | BofA Securities | Buy |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-22 | 開始されました | H.C. Wainwright | Buy |
| 2020-11-17 | 開始されました | Cowen | Outperform |
| 2020-11-17 | 開始されました | Goldman | Buy |
| 2020-11-17 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-17 | 開始されました | Wedbush | Outperform |
すべてを表示
Foghorn Therapeutics Inc (FHTX) 最新ニュース
FY2028 EPS Estimate for Foghorn Therapeutics Cut by Analyst - Defense World
HC Wainwright Has Positive Forecast for FHTX FY2024 Earnings - Defense World
Charles Schwab Investment Management Inc. Grows Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Wedbush Reduces Earnings Estimates for Foghorn Therapeutics - MarketBeat
HC Wainwright Issues Optimistic Estimate for FHTX Earnings - MarketBeat
Foghorn Therapeutics price target lowered to $13 from $20 at H.C. Wainwright - Yahoo Finance
Short Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Decreases By 9.7% - MarketBeat
Foghorn Therapeutics shares target cut, buy rating on positive outlook By Investing.com - Investing.com Canada
Foghorn Therapeutics (NASDAQ:FHTX) Given New $14.00 Price Target at Jefferies Financial Group - Defense World
Foghorn Therapeutics' (FHTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Foghorn Therapeutics Advances Precision Oncology Pipeline - Yahoo Finance
Foghorn Therapeutics' SWOT analysis: chromatin pioneer's stock faces pivotal moment - Investing.com Canada
Foghorn Therapeutics Stock Slides On Cancer Drug Development Halt, But Retail Remains Upbeat - MSN
Jefferies Financial Group Has Lowered Expectations for Foghorn Therapeutics (NASDAQ:FHTX) Stock Price - MarketBeat
Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower - Benzinga
Foghorn Therapeutics Inc. Provides Update on FHD-286 Clinical Development Program and Strategic Priorities - Marketscreener.com
Foghorn shifts focus from AML drug FHD-286 - Investing.com
Foghorn Therapeutics Ends Solo Development of FHD-286 - MarketWatch
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities - The Manila Times
Foghorn Therapeutics Halts Key AML Drug Development After Phase 1 Results Fall Short - StockTitan
After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX) - MSN
This Foghorn Therapeutics Insider Reduced Their Stake By 13% - Simply Wall St
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why - MSN
How the (FHTX) price action is used to our Advantage - Stock Traders Daily
Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High? - MSN
(FHTX) Technical Pivots with Risk Controls - Stock Traders Daily
Foghorn Therapeutics patents new CBP degradation inducers - BioWorld Online
Foghorn Therapeutics (FHTX) Collaborates with Eli Lilly and Surpasses Q3 Expectations - Nasdaq
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - The Manila Times
(FHTX) Trading Report - Stock Traders Daily
What is HC Wainwright’s Estimate for FHTX FY2024 Earnings? - Defense World
Wedbush Lifts Earnings Estimates for Foghorn Therapeutics - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think - Simply Wall St
Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter Report - Yahoo Finance
Research Analysts Issue Forecasts for FHTX FY2024 Earnings - MarketBeat
HC Wainwright Has Bullish Estimate for FHTX FY2024 Earnings - MarketBeat
We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth Carefully - Yahoo Finance
Foghorn Therapeutics Inc (FHTX) Q3 2024 Earnings: Revenue Surpas - GuruFocus.com
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates - MSN
Foghorn Therapeutics Reports Third Quarter Highlights - TipRanks
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update - GlobeNewswire
(FHTX) Investment Report - Stock Traders Daily
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Sold by Raymond James & Associates - Defense World
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk - Simply Wall St
Foghorn Therapeutics Inc (FHTX) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):